Predictive Patient Stability Technology Developed at MCIRCC gets FDA Market Approval

Fifth Eye Inc. was recently granted FDA De Novo classification for its Analytic for Hemodynamic Instability (AHI), a device that predicts if a patient will become unstable earlier than traditional vital signs. Technology driving AHI was developed at the University of Michigan Center for Integrative Research in Critical Care (MCIRCC).